BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20139775)

  • 1. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Various 'dendritic cell antigens' are already expressed on uncultured blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Dreyssig J; Kremser A; Liepert A; Grabrucker C; Freudenreich M; Schmid C; Kroell T; Scholl N; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer HM
    Immunotherapy; 2011 Sep; 3(9):1113-24. PubMed ID: 21913833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
    Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
    Bund D; Buhmann R; Gökmen F; Kremser A; Dreyssig J; Kolb HJ; Schmetzer HM
    Cell Immunol; 2010; 263(1):88-98. PubMed ID: 20347071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia.
    Westers TM; Stam AG; Scheper RJ; Regelink JC; Nieuwint AW; Schuurhuis GJ; van de Loosdrecht AA; Ossenkoppele GJ
    Cancer Immunol Immunother; 2003 Jan; 52(1):17-27. PubMed ID: 12536236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals.
    Kharfan-Dabaja M; Ayala E; Lindner I; Cejas PJ; Bahlis NJ; Kolonias D; Carlson LM; Lee KP
    Cancer Immunol Immunother; 2005 Jan; 54(1):25-36. PubMed ID: 15693136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.
    Köhler T; Plettig R; Wetzstein W; Schmitz M; Ritter M; Mohr B; Schaekel U; Ehninger G; Bornhäuser M
    Stem Cells; 2000; 18(2):139-47. PubMed ID: 10742386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia.
    Pospísilová D; Borovicková J; Poloucková A; Spísek R; Sedivá A; Hrusák O; Starý J; Bartůnková J
    Cancer Immunol Immunother; 2002 Apr; 51(2):72-8. PubMed ID: 11904731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system.
    Zhong RK; Loken M; Lane TA; Ball ED
    Cytotherapy; 2006; 8(1):3-12. PubMed ID: 16627340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts.
    Gong J; Koido S; Kato Y; Tanaka Y; Chen D; Jonas A; Galinsky I; DeAngelo D; Avigan D; Kufe D; Stone R
    Leuk Res; 2004 Dec; 28(12):1303-12. PubMed ID: 15475072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
    He X; You S; Bian S
    Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.